Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8566 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD8566 | DRUG | Single 6 mg oral solution dose |
| AZD8566 IV carbon labelled | DRUG | Single 10 mcg intravenous carbon-14 microtracer dose |
| Placebo | DRUG | 10ml oral solution administered once a day over 10 days. |
Inclusion Criteria: * Provision of written informed consent * Clinically normal physical findings and laboratory values as judged by the investigator with normal ECG * Females who are permanently or surgically sterile or post-menopausal and males Exclusion Criteria: * History of any convulsions o...
AZD8566 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in Phase 1 clinical trials in healthy volunteers in the United Kingdom, with a focus on safety, tolerability, and pharmacokinetics. No therapeutic indication for AZD8566 has been disclosed.
AZD8566 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the Phase 1 clinical program for the compound, including studies conducted in the United Kingdom in healthy volunteers.
AZD8566 is in Phase 1 clinical development. Three Phase 1 trials have been completed, and no later-phase studies have been reported. AZD8566 is investigational and has not been approved by the FDA for any indication.
AZD8566 has been evaluated in three completed Phase 1 trials: NCT00749333, a single-dose safety, tolerability, and pharmacokinetics study in 108 healthy volunteers; NCT00844103, a multiple-dose study in 36 healthy volunteers; and NCT00866385, a food effect and microtracer study in 21 healthy volunteers.
The AZD8566 Phase 1 program enrolled 165 healthy volunteers across three completed trials in the United Kingdom. The studies were randomized, double-blind, and placebo-controlled, and evaluated single and multiple doses of AZD8566 as well as food effects on the compound.